Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

ction of the BLA by the end of this year, which will complete the application. If approved, metreleptin would be the first therapy indicated specifically for the treatment of diabetes and high triglycerides in patients with lipodystrophy, and the first approved therapeutic use of metreleptin.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties.  The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amyli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced positive results from ... clostridium histolyticum (or CCH) for the treatment of ... In the Phase 2a trial, all three doses ... (0.84mg)) showed an improvement in the appearance of ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kentucky blocked the sale of more ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... genetics,(Nasdaq: DCGN ) today announced the filing ... the company,s novel small-molecule modulator,of phosphodiesterase 4 (PDE4), ... compound is being developed as a new and ... loss and cognitive deficits associated,with Alzheimer,s disease and ...
... from the,French Medicine Agency (AFSSAPS) the authorization to ... PL37, its lead compound for oral,treatment of neuropathic ... pain condition, with an estimated,prevalence in the world,s ... most,recent surveys, with many causes such as shingles, ...
Cached Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2
(Date:8/21/2014)... Chicago, IL (PRWEB) August 21, 2014 ... its 33rd annual Inc. 500|5000, an exclusive ranking of ... most comprehensive look at the most important segment of ... Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow, and many other ... Inc. 500|5000. , “Centurion is proud to have been ...
(Date:8/21/2014)... MISSOULA, Mont. (PRWEB) August 21, 2014 She ... struck blind and brain injured after a surgery to correct ... “He Works All Things Together…” author Rebecca Strom-Stewart shares her ... misguided good intentions that led to a miscarriage of justice ... trudge through the tunnel of darkness and into the light,” ...
(Date:8/21/2014)... Raton, FL (PRWEB) August 21, 2014 Teen ... people in Boca Raton, FL. The rising numbers of young ... been staggering. To help make a difference in the community, ... provide a valuable resource for teens seeking to overcome something ... to help parents and their teens find the best teen ...
(Date:8/21/2014)... Charleston, SC (PRWEB) August 21, 2014 ... one of seven start-ups selected to participate in ... program provides entrepreneur mentorship, curriculum sessions and valuable ... scalable businesses in the region. Each start-up selected ... and support in order to help businesses grow ...
(Date:8/21/2014)... 21, 2014 InSilico Medicine, ... and addressing the challenges of a rapidly ... for signalome-wide pathway analysis. This new ... analysis of gene expression data obtained using ... in the journal Frontiers in Molecular Biosciences, ...
Breaking Medicine News(10 mins):Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:The Dramatic, Uplifting Story from a Brain Injured Woman 2Health News:New Helpline Provides Hope for Troubled Teens in Boca Raton 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... PUA Forums.com, the ... meet and charm women, is now also helping men take it to the next level - ... ... for dating advice that has already helped thousands of men learn how to meet and charm ...
... ... the rage. Today more than ever, people are turning to books on attaining success to ... lumped together, a recent discovery by Steve Paris, CEO of Orne Publishing, is about to turn ... , ...
... , ... days in June, QuickMedical® converted their 11,000 square foot warehouse into a showcase for ... of free food and prizes, the QuickMedical® Open House and Benefit was an event ... ...
... ... web portal that provides a comprehensive view of California public policy and legislative issues. ... tracking in one site. , ... (PRWEB) June 28, 2010 -- The ‘LegisWeb Eye’ launches on July 1st, bringing a new ...
... lower their cholesterol are 30 percent less likely to see ... who do not use the drugs, according to researchers at ... of the drugs were associated with lower risk of recurrence. ... "The findings add another layer of evidence ...
... , SUNDAY, June 27 (HealthDay News) -- Scientists have located ... predisposition for type 2 diabetes, bringing the total number of ... At this point, the findings don,t mean much for patients ... treatments. "From here, to apply this clinically is going ...
Cached Medicine News:Health News:PUA Forums Will Help You Get A Girlfriend 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 3Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 2Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 3Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 2Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 3Health News:Statins associated with lower cancer recurrence following prostatectomy 2Health News:More Genes Implicated in Type 2 Diabetes 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: